Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Multiple comparisons in complex clinical trial designs.

Hung HM, Wang SJ.

Biom J. 2013 May;55(3):420-9. doi: 10.1002/bimj.201200048. Epub 2013 Feb 18. Review.

PMID:
23620458
2.

Challenges to multiple testing in clinical trials.

James Hung HM, Wang SJ.

Biom J. 2010 Dec;52(6):747-56. doi: 10.1002/bimj.200900206.

PMID:
20589856
3.

How to deal with multiple endpoints in clinical trials.

Neuhäuser M.

Fundam Clin Pharmacol. 2006 Dec;20(6):515-23. Review.

PMID:
17109645
4.

Partition testing in dose-response studies with multiple endpoints.

Liu Y, Hsu J, Ruberg S.

Pharm Stat. 2007 Jul-Sep;6(3):181-92.

PMID:
17654696
5.

Statistical considerations for the next generation of clinical trials.

Wu W, Shi Q, Sargent DJ.

Semin Oncol. 2011 Aug;38(4):598-604. doi: 10.1053/j.seminoncol.2011.05.014. Review.

PMID:
21810519
6.

Some controversial multiple testing problems in regulatory applications.

Hung HM, Wang SJ.

J Biopharm Stat. 2009;19(1):1-11; discussion 12-41. doi: 10.1080/10543400802541693.

PMID:
19127460
7.

Gatekeeping procedures with clinical trial applications.

Dmitrienko A, Tamhane AC.

Pharm Stat. 2007 Jul-Sep;6(3):171-80.

PMID:
17583553
8.

Bayesian design and analysis of composite endpoints in clinical trials with multiple dependent binary outcomes.

Zaslavsky BG.

Pharm Stat. 2013 Jul-Aug;12(4):207-12. doi: 10.1002/pst.1572. Epub 2013 Apr 29.

PMID:
23625660
9.

Analysis strategies for adaptive designs with multiple endpoints.

Chang M, Chow SC.

J Biopharm Stat. 2007;17(6):1189-200. Erratum in: J Biopharm Stat. 2008;18(2):402.

PMID:
18027225
10.

Power and sample size when multiple endpoints are considered.

Senn S, Bretz F.

Pharm Stat. 2007 Jul-Sep;6(3):161-70.

PMID:
17674404
11.

Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.

Schmidt R, Burkhardt B, Faldum A.

Methods Inf Med. 2015;54(5):434-46. doi: 10.3414/ME14-02-0023. Epub 2015 Oct 2.

PMID:
26429500
12.

Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.

Polley MY, Cheung YK.

Biometrics. 2008 Mar;64(1):232-41. Epub 2007 Jun 15.

PMID:
17573866
13.

An efficient method for accommodating potentially underpowered primary endpoints.

Li J, Mehrotra DV.

Stat Med. 2008 Nov 20;27(26):5377-91. doi: 10.1002/sim.3369.

PMID:
18759248
14.

A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.

Sugimoto T, Sozu T, Hamasaki T.

Pharm Stat. 2012 Mar-Apr;11(2):118-28. doi: 10.1002/pst.505.

PMID:
22415870
15.

The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.

Lonn E.

Pharmacoepidemiol Drug Saf. 2001 Oct-Nov;10(6):497-508. Review.

PMID:
11828831
16.

Some challenges with statistical inference in adaptive designs.

Hung HM, Wang SJ, Yang P.

J Biopharm Stat. 2014;24(5):1059-72. doi: 10.1080/10543406.2014.925911.

PMID:
24915027
17.
18.

Design and analysis issues of multiregional clinical trials with different regional primary endpoints.

Tsou HH, Tsong Y, Chang WJ, Dong X, Hsiao CF.

J Biopharm Stat. 2012 Sep;22(5):1051-9. doi: 10.1080/10543406.2012.701586. Review.

PMID:
22946949
19.

Use of composite endpoints in clinical trials.

Sankoh AJ, Li H, D'Agostino RB Sr.

Stat Med. 2014 Nov 30;33(27):4709-14. doi: 10.1002/sim.6205. Epub 2014 May 15.

PMID:
24833282
20.

Supplemental Content

Support Center